Latest news with #IDEXXLaboratories
Yahoo
3 days ago
- Business
- Yahoo
Here's What to Expect From IDEXX Laboratories' Next Earnings Report
Westbrook, Maine-based IDEXX Laboratories, Inc. (IDXX) develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries. Valued at a market cap of $42.7 billion, the company also offers a range of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. It is scheduled to announce its fiscal Q2 earnings for 2025 before the market opens on Monday, Aug. 4. Before this event, analysts project this pet healthcare company to report a profit of $3.29 per share, up 34.8% from $2.44 per share in the year-ago quarter. The company has surpassed Wall Street's bottom-line estimates in three of the last four quarters, while missing on another occasion. Its earnings of $2.96 per share in the previous quarter topped the consensus estimates by 1.4%. Palantir Just Launched Warp Speed for Warships. Does That Make PLTR Stock a Buy? This Analyst Just Doubled His Price Target on AMD Stock How High Can Nvidia Stock Go as Jensen Huang Heads to China? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! For the full year, analysts expect IDXX to report EPS of $12.18, up 14.2% from $10.67 in fiscal 2024. Its EPS is expected to further grow 12.5% year-over-year to $13.70 in fiscal 2026. IDXX has lagged behind the S&P 500 Index's ($SPX) 11.6% return over the past 52 weeks, with its shares up 7.9% during this period. However, it has outpaced the Health Care Select Sector SPDR Fund's (XLV) 8.9% downtick over the same time frame. On May 1, shares of IDXX rose 9% after its Q1 earnings release, despite missing the revenue estimates. The company's revenue improved 3.6% year-over-year to $998.4 million, but fell short of consensus expectations. However, on the upside, both its gross and operating profit margins expanded from the year-ago quarter, leading to a 5.3% increase in its EPS to $2.96, which topped the analyst estimates by 1.4%. IDEXX also raised its fiscal 2025 guidance, now projecting revenue between $4.1 billion and $4.2 billion, and EPS in the range of $11.93 to $12.43. This might have further bolstered investor confidence. Wall Street analysts are moderately optimistic about IDXX's stock, with a "Moderate Buy" rating overall. Among 11 analysts covering the stock, six recommend "Strong Buy," one indicates a "Moderate Buy," and four advise "Hold.' The mean price target for IDXX is $549.50, indicating a 3.4% potential upside from the current levels. On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
Business Wire
24-06-2025
- Business
- Business Wire
IDEXX Laboratories to Release 2025 Second Quarter Financial Results
WESTBROOK, Maine--(BUSINESS WIRE)-- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 second quarter financial results for Monday, August 4, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. EDT on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q2 2025 Earnings Snapshot through a link on the IDEXX website, An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen to the live conference call, please dial 1-800-289-0462 or 1-323-794-2442 and reference passcode 595638. 2025 Investor Day IDEXX Laboratories, Inc. will host its 2025 Investor Day on Thursday, August 14, 2025, at its corporate headquarters in Westbrook, Maine from 8:00 am to approximately 12:00 pm EDT. A live webcast of the presentations will be available on Advance registration for the in-person event is required; institutional investors and analysts interested in attending should contact investorrelations@ Additional information on IDEXX's Investor Day will be provided closer to the date of the event. About IDEXX Laboratories, Inc. IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500 ® Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit
Yahoo
05-06-2025
- Business
- Yahoo
IDEXX Laboratories (NasdaqGS:IDXX) Launches Catalyst Cortisol Test for Canine Health
IDEXX Laboratories recently introduced its Catalyst® Cortisol Test, an advance in veterinary diagnostics, and reported an earnings growth with a raised revenue guidance for 2025. Furthermore, the company repurchased 930,800 shares, indicating strong financial health. These developments likely supported IDEXX's 22% share price increase over the last quarter. Meanwhile, broader market movements were relatively modest, with indices experiencing slight gains amid optimistic trade discussions between the U.S. and China and positive economic data. IDEXX's performance was possibly bolstered by its innovative launches and solid financials, in line with buoyant market sentiments. We've spotted 1 risk for IDEXX Laboratories you should be aware of. Find companies with promising cash flow potential yet trading below their fair value. The introduction of the Catalyst® Cortisol Test and share repurchase strengthens IDEXX Laboratories' position in veterinary diagnostics, potentially boosting revenue and earnings forecasts through increased diagnostic usage and market expansion. Over the past five years, IDEXX's total shareholder returns increased by 63.06%, including price movements and dividends, reflecting consistent long-term growth despite some market volatilities. In contrast, IDEXX underperformed the US Medical Equipment industry over the past year, which returned 9%. Though the current share price increase in the last quarter aligns with recent innovations and improved guidance, it trades close to the consensus price target of US$496.54. This suggests analysts view the company as nearing fair value. However, continued product innovations and strategic international expansions might influence future market valuations as IDEXX strives to enhance revenue and earnings growth amid potential challenges such as trade tensions and changing clinical visits. Our comprehensive valuation report raises the possibility that IDEXX Laboratories is priced higher than what may be justified by its financials. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:IDXX. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Cision Canada
05-06-2025
- Health
- Cision Canada
Third Expansion of IDEXX's Catalyst Platform in Under a Year Delivers Critical Insights to Veterinarians Evaluating Canine Patients for Endocrine Disorders
WESTBROOK, Maine, June 5, 2025 /CNW/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the launch of the Catalyst ® Cortisol Test, which measures real-time quantitative cortisol concentrations to support the diagnosis of Addison's disease and diagnosis and management of Cushing's syndrome in dogs. IDEXX's Catalyst Cortisol Test is the third menu expansion in under a year for the Catalyst platform, further advancing the diagnostic capabilities available to veterinary practices at the point-of-care. Addison's disease, often called "the great pretender," is a life-threatening condition caused by low cortisol and is difficult to diagnose due to its common and nonspecific clinical signs that can resemble those of other illnesses, such as gastroenteritis or kidney disease. Early detection is critical, as timely treatment can be lifesaving. Cushing's syndrome, driven by excess cortisol, is a common endocrine disorder in older dogs, and certain breeds are at an increased risk. Cushing's syndrome requires long-term management, and if left untreated, it can significantly diminish quality of life. IDEXX's Catalyst Cortisol Test enables veterinarians to confidently and accurately diagnose or rule out Addison's disease and Cushing's syndrome during the patient visit, allowing for immediate treatment or adjustments to ongoing care management. This workflow efficiency continues throughout the patient journey with monitoring capabilities that enable tailored treatment adjustments, improving long-term care for patients with Cushing's syndrome. "The Catalyst Cortisol Test is an accurate and highly requested test that addresses a critical need for our customers and equips veterinarians with built-in results interpretation for prompt action, supporting better health outcomes for dogs," said Jay Mazelsky, President and Chief Executive Officer of IDEXX. "Continuing to expand the Catalyst platform reinforces our Technology for Life promise, offering our customers solutions that advance in capabilities over time to expand clinical insights and care delivery at the point-of-care." The IDEXX Catalyst Cortisol Test features: Accuracy: Provides quantitative results in-clinic that align with IDEXX Reference Laboratories, enabling veterinarians to confidently diagnose or rule out Addison's disease and Cushing's syndrome. Interpretive guidance: Integrates with the IDEXX Vetlab ® Station and VetConnect ® PLUS, providing results-specific interpretation in real-time during the patient visit. Efficiency: The Catalyst Cortisol Test's load-and-go workflow can run alone or with additional chemistry tests using a single sample for comprehensive diagnostic insights into patient health status. This workflow saves hands-on sample preparation time for veterinary technicians and ensures repeatable results. "A reliable in-house test is game-changing—it enables faster diagnosis and treatment of a life-threatening Addisonian crisis in dogs," said Patty Lathan, VMD, MS, DACVIM (SAIM).* "Additionally, by delivering accurate results during the visit, it supports timely care and streamlines daily workflows for busy veterinary teams." The Catalyst Cortisol Test will be available in the U.S. and Canada at the end of July 2025, with a global rollout to the installed base of more than 75,000 Catalyst chemistry analyzers expected to start in the third quarter of 2025. For more information, visit the IDEXX Catalyst test menu web page. About IDEXX IDEXX Laboratories, Inc., is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500® Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit: Note Regarding Forward-Looking Statements This news release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "expects," "may," "anticipates," "intends," "would," "will," "plans," "believes," "estimates," "should," "project," and similar words and expressions. These forward-looking statements are intended to provide our current expectations or forecasts of future events; are based on current estimates, projections, beliefs, and assumptions; and are not guarantees of future performance. Actual events or results may differ materially from those described in the forward-looking statements. These statements are subject to risks, uncertainties, assumptions, and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by IDEXX pursuant to United States securities laws contain discussions of some of these risks and uncertainties. IDEXX assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers are advised to review IDEXX's filings with the United States Securities and Exchange Commission (which are available from the SEC's EDGAR database at and via IDEXX's website at
Business Wire
13-05-2025
- Business
- Business Wire
IDEXX Laboratories to Present at Stifel Conference and Announces 2025 Investor Day
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Andrew Emerson, Executive Vice President and Chief Financial Officer, and Tina Hunt, Executive Vice President, Global Strategy and Commercial, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 28, 2025 from 10:55 am – 11:25 am (EDT). A live audio webcast of the presentation will be available through a link on the IDEXX website, An archived edition of the presentation will be available via the same link. 2025 Investor Day IDEXX Laboratories, Inc. also announced today that it will host its 2025 Investor Day on Thursday, August 14, 2025 at its corporate headquarters in Westbrook, Maine from approximately 8:00 am to 12:00 pm (EDT). A live webcast of the presentations will be available on Advance registration for the in-person event is required; institutional investors and analysts interested in attending should contact investorrelations@ Additional information on IDEXX's Investor Day will be provided closer to the date of the event. About IDEXX Laboratories, Inc. IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500 ® Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries. For more information about IDEXX, visit
